Investigating how the EGF receptor is taken up by cells and its role in signaling
Official title: EGF Receptor Endocytosis: Mechanisms and Role in Signaling
Funded at University of Pittsburgh at Pittsburgh · NIH-11060887 · Data updated 2026-11-12
This study is looking at how a specific protein called EGFR is taken into cells and how this affects how cells communicate, which could help us understand its role in diseases like cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | June 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $397,500 |
| NIH project number | 5R35GM148363-03 |
| Project ID | NIH-11060887 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who may have conditions related to EGFR signaling, such as certain cancers.
✕Less likely to help
Patients who are under 21 years old or do not have conditions related to EGFR signaling may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms by which the epidermal growth factor receptor (EGFR) is internalized by cells and how this process affects cellular signaling. Using advanced single-cell and high-throughput methods, the study aims to monitor the trafficking of gene-edited EGFR in real-time. By examining how stress and other factors influence EGFR endocytosis, the research seeks to clarify the relationship between receptor signaling and cellular responses. This could provide insights into how EGFR functions in various diseases, including cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved therapeutic strategies targeting EGFR-related pathways in diseases such as cancer.
How similar studies have gone: Previous research has shown success in understanding receptor signaling mechanisms, but the specific focus on EGFR endocytosis and its regulatory pathways is relatively novel.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Sorkin, Alexander D — University of Pittsburgh at Pittsburgh
- Study coordinator: Sorkin, Alexander D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.